{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T12:39:10Z","timestamp":1788439150510,"version":"build-2803163510"},"reference-count":29,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100013064","name":"Key Research and Development Program of Jiangxi Province","doi-asserted-by":"publisher","award":["BE2022711"],"award-info":[{"award-number":["BE2022711"]}],"id":[{"id":"10.13039\/501100013064","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82350102"],"award-info":[{"award-number":["82350102"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012217","name":"Xuzhou Medical University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012217","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["celltherapyjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytotherapy"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.jcyt.2024.08.007","type":"journal-article","created":{"date-parts":[[2024,8,24]],"date-time":"2024-08-24T01:02:19Z","timestamp":1724461339000},"page":"16-24","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Comprehensive characterization of cytopenia after chimeric antigen receptor-T cell infusion in patients with relapsed or refractory multiple myeloma"],"prefix":"10.1016","volume":"27","author":[{"given":"Hai","family":"Cheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingyan","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dandan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yegan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingjun","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zihan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaying","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Sang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunming","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenyu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cai","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianlin","family":"Qiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingyun","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingyu","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junnian","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kailin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3767-9283","authenticated-orcid":false,"given":"Jiang","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcyt.2024.08.007_bib0001","doi-asserted-by":"crossref","first-page":"e321","DOI":"10.1634\/theoncologist.2019-0233","article-title":"The European Medicines Agency Review of Kymriah (Tisagenlecleucel) for the treatment of acute lymphoblastic leukemia and diffuse large B-Cell lymphoma","volume":"25","author":"Ali","year":"2020","journal-title":"Oncologist"},{"key":"10.1016\/j.jcyt.2024.08.007_bib0002","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"The Lancet"},{"key":"10.1016\/j.jcyt.2024.08.007_bib0003","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1200\/JCO.2018.77.8084","article-title":"T cells genetically modified to express an anti\u2013B-cell maturation antigen chimeric antigen receptor cause remissions of poor-prognosis relapsed multiple myeloma","volume":"36","author":"Brudno","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jcyt.2024.08.007_bib0004","doi-asserted-by":"crossref","first-page":"2821","DOI":"10.1182\/blood-2021-150124","article-title":"Sustainable efficacy and safety results from Lummicar study 1: a phase 1\/2 study of fully human B-cell maturation antigen-specific CAR T cells (CT053) in Chinese subjects with relapsed and\/or refractory multiple myeloma","volume":"138","author":"Chen","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2024.08.007_bib0005","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1038\/s41409-019-0487-3","article-title":"Early and late hematologic toxicity following CD19 CAR-T cells","volume":"54","author":"Fried","year":"2019","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jcyt.2024.08.007_bib0006","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1182\/blood-2021-151935","article-title":"Integrated analysis of B-cell maturation antigen-specific CAR T cells (CT053) in relapsed and refractory multiple myeloma subjects by high-risk factors","volume":"138","author":"Fu","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2024.08.007_bib0007","doi-asserted-by":"crossref","first-page":"3154","DOI":"10.1182\/blood-2019-127608","article-title":"Efficacy and safety of CAR-T therapy with safety switch targeting Bcma for patients with relapsed\/refractory multiple myeloma in a phase 1 clinical study","volume":"134","author":"Fu","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2024.08.007_bib0008","doi-asserted-by":"crossref","first-page":"3776","DOI":"10.1182\/bloodadvances.2020002509","article-title":"Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignancies","volume":"4","author":"Jain","year":"2020","journal-title":"Blood Adv"},{"issue":"Suppl. 3","key":"10.1016\/j.jcyt.2024.08.007_bib0009","first-page":"1","article-title":"Japanese translation of common terminology criteria for adverse events (CTCAE), and instructions and guidelines","volume":"9","year":"2004","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.jcyt.2024.08.007_bib0010","doi-asserted-by":"crossref","first-page":"978","DOI":"10.3324\/haematol.2019.238634","article-title":"Immune reconstitution and associated infections following axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma","volume":"106","author":"Logue","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.jcyt.2024.08.007_bib0011","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jcyt.2024.08.007_bib0012","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1186\/s13045-021-01170-7","article-title":"A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma","volume":"14","author":"Li","year":"2021","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.jcyt.2024.08.007_bib0013","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1182\/blood-2019-128468","article-title":"Efficacy and safety of fully human Bcma targeting CAR T cell therapy in relapsed\/refractory multiple myeloma","volume":"134","author":"Li","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2024.08.007_bib0014","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1182\/blood-2018-99-116898","article-title":"T cells expressing anti B-cell maturation antigen chimeric antigen receptors for plasma cell malignancies","volume":"132","author":"Li","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2024.08.007_bib0015","doi-asserted-by":"crossref","first-page":"3243","DOI":"10.1182\/blood-2021-149738","article-title":"Cytopenias in CAR-T cell therapy and use of transfusion resources in adult patients with lymphoproliferative disorders","volume":"138","author":"Mezquita","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2024.08.007_bib0016","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcyt.2024.08.007_bib0017","doi-asserted-by":"crossref","first-page":"e459","DOI":"10.1016\/S2352-3026(24)00077-2","article-title":"Immune effector cell-associated haematotoxicity after CAR T-cell therapy: from mechanism to management","volume":"11","author":"Rejeski","year":"2024","journal-title":"The Lancet Haematology"},{"key":"10.1016\/j.jcyt.2024.08.007_bib0018","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1182\/bloodadvances.2019000952","article-title":"Comparing CAR T-cell toxicity grading systems: application of the ASTCT grading system and implications for management","volume":"4","author":"Pennisi","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.jcyt.2024.08.007_bib0019","article-title":"Prolonged hematological toxicity in patients receiving BCMA\/CD19 CAR-T-cell therapy for relapsed or refractory multiple myeloma","volume":"13","author":"Li","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.jcyt.2024.08.007_bib0021","doi-asserted-by":"crossref","first-page":"8901","DOI":"10.2147\/CMAR.S321202","article-title":"Cytopenias After CD19 chimeric antigen receptor T-cells (CAR-T) therapy for diffuse large B-cell lymphomas or transformed follicular lymphoma: a single institution experience","volume":"13","author":"Schaefer","year":"2021","journal-title":"CMAR Volume"},{"key":"10.1016\/j.jcyt.2024.08.007_bib0020","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s13045-023-01465-x","article-title":"The CAR-HEMATOTOX score as a prognostic model of toxicity and response in patients receiving BCMA-directed CAR-T for relapsed\/refractory multiple myeloma","volume":"16","author":"Rejeski","year":"2023","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.jcyt.2024.08.007_bib0024","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1111\/j.1600-0609.2010.01466.x","article-title":"High serum lactate dehydrogenase adds prognostic value to the international myeloma staging system even in the era of novel agents","volume":"85","author":"Terpos","year":"2010","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.jcyt.2024.08.007_bib0025","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1111\/j.1600-0609.2005.00532.x","article-title":"Multiple myeloma in elderly patients: prognostic factors and outcome","volume":"75","author":"Anagnostopoulos","year":"2005","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.jcyt.2024.08.007_bib0026","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s00277-010-1130-y","article-title":"Prognostic factor analyses of myeloma survival with intergroup trial S9321 (INT 0141): examining whether different variables govern different time segments of survival","volume":"90","author":"Barlogie","year":"2010","journal-title":"Ann Hematol"},{"key":"10.1016\/j.jcyt.2024.08.007_bib0027","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/ajh.26113","article-title":"Prolonged hematologic toxicity following treatment with chimeric antigen receptor T cells in patients with hematologic malignancies","volume":"96","author":"Nagle","year":"2021","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jcyt.2024.08.007_bib0022","article-title":"New-onset severe cytopenia after CAR-T cell therapy: analysis of 76 patients with relapsed or refractory acute lymphoblastic leukemia","volume":"11","author":"Wang","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.jcyt.2024.08.007_bib0028","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1200\/JCO.21.01676","article-title":"Long-term follow-up of combination of B-cell maturation antigen and CD19 chimeric antigen receptor T cells in multiple myeloma","volume":"40","author":"Wang","year":"2022","journal-title":"JCO"},{"key":"10.1016\/j.jcyt.2024.08.007_bib0029","doi-asserted-by":"crossref","first-page":"e521","DOI":"10.1016\/S2352-3026(19)30115-2","article-title":"A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial","volume":"6","author":"Yan","year":"2019","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.jcyt.2024.08.007_bib0030","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s13045-018-0681-6","article-title":"A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma","volume":"11","author":"Zhao","year":"2018","journal-title":"J Hematol Oncol"}],"container-title":["Cytotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324924008296?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324924008296?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T20:10:51Z","timestamp":1762546251000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1465324924008296"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S1465324924008296"],"URL":"https:\/\/doi.org\/10.1016\/j.jcyt.2024.08.007","relation":{},"ISSN":["1465-3249"],"issn-type":[{"value":"1465-3249","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comprehensive characterization of cytopenia after chimeric antigen receptor-T cell infusion in patients with relapsed or refractory multiple myeloma","name":"articletitle","label":"Article Title"},{"value":"Cytotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcyt.2024.08.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 International Society for Cell & Gene Therapy. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}